]This poster has a different perception on Ariads performance probably as he is relatively new to the company as opposed to many of us here who have been around for years and have a very low cost basis. The long timers like myself are quite content to let it play it out over the next few years as long as the news out of the clinics remains good. In the long run we may have a either a very satisfactory result or a life changing result. Ponatinib seems at this point to preclude a less than satisfactory outcome. Therefore will little downside and a relatively unlimited upside, I can't think of a better place to keep my money now, can anyone else?
News 
Market Data 
Discover 
